ClinicalTrials.gg
TerminatedNCT00948389Updated Aug 31, 2012Results posted

Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

A Phase 1/2 interventional study of Dasatinib and Lomustine in Glioblastoma, sponsored by Bristol-Myers Squibb. Terminated at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-31.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Inability to meet protocol objectives

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing lomustine in Glioblastoma — 3 open to participants now, 4 under way, 2 of them phase 3. Lomustine · Glioblastoma.

Enrollment
16th of 22
28 · median 68
Started
2009
the only one that year
Phase 1/2
2 of 22
none open now
Registered
5th of 22
by date
Lead sponsor
1 of 22
Bristol-Myers Squibb

Among the 22 studies testing lomustine in Glioblastoma, this one is the 16th largest by enrollment, is the only one that started in 2009, is one of 2 in phase 1/2, and was the 5th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 467 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

3 of the 22 studies testing lomustine in Glioblastoma are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lomustine

Lomustine: first FDA approval 1976 (GLEOSTINE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing lomustine in Glioblastoma, or all of them as a file.
02

Study summary

To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma

03

Conditions studied

  • Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with histological or cytological proven glioblastoma multiforme
  • Recurrent or progressive disease documented by magnetic resonance imaging (MRI)
  • World Health Organization (WHO) Performance status 0 - 2
  • Patient may have been operated for recurrence
  • For non operated patients, recurrent disease must be at least one bidimensionally measurable target lesion with one diameter of at least 2cm
  • Patients must be on a stable or decreasing dose of for at least 1 week prior to baseline MRI

Exclusion criteria

Exclusion Criteria:

  • Patients with histological or cytological proven glioblastoma multiforme
  • Completion of radiotherapy to the brain less than 3 months prior to registration/randomization
  • Prior treatment with high dose radiotherapy, stereotactic radiosurgery or internal radiation therapy
  • Previous or current at other sites within prior 3 years
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Active comparator
    Dasatinib

    Drug: Dasatinib

  • Active comparator
    Lomustine

    Drug: Lomustine

Interventions

  • Tablets, Oral, 100 mg, Once or Twice daily (depending on safety cohort), Until progression or toxicity

    Also known as: BMS-354825

  • Tablets, Oral, 110 mg/m², Every 6 weeks, until progression or toxicity

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs

    SAE=any untoward medical event that results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires inpatient hospitalization or prolongation. AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Treatment-related(Tx-R)=certainly, probably, possibly related and unknown relationship to study drug. AE grades(Gr) 1=Mild; 2=Moderate; 3=Severe; 4=Life-threatening.

    Time frame: Assessed at baseline, every 2 weeks during cycles 1-6 (6-week cycles), and every 6 weeks after cycle 6. Median number of cycles = 1.0 (range: 1.0 - 7.0).

  2. Number of Participants With Dose-limiting Toxicities (DLTs)

    Grades (gr) according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE), version 3.0. DLTs were defined as adverse drug reactions as follows: absolute neutrophil counts \<0.5x10\^9/L (gr4) lasting for 7 consecutive days; febrile neutropenia (neutrophil count \<1x10\^9/L and fever of \>=38.5°C); thrombocytopenia (gr4); any gr3/4 nonhematological toxicity except nausea, vomiting and fever which could be rapidly controlled with appropriate measures; any toxicity which did not allow administering at least 70% of the intended dose intensity for both agents.

    Time frame: The duration for observation of DLT was 2 6-week cycles in participants with escalated dose (QD to BID) and 1 6 -week cycle for participants starting with BID regime. For participants receiving dasatinib at 150 mg, DLTs were only documented over cycle 1.

  3. Deaths Within 30 Days of Protocol Treatment Discontinuation

    Time frame: From time of randomization through within 30 days after protocol treatment discontinuation. Median (full range) number of 6-week treatment cycles was 1.0 (1.0-7.0).

  4. Number of Participants With Worst Grade of Hematological Toxicity Per NCI CTCAE Version 3.0 Criteria

    Neutrophils (neutropenia): Grade (gr)1 \<LLN-1500/mm3; Gr2 \<1500-1000/mm3; Gr3 \<1000-500/mm3; Gr4 \<500/mm3. Leukocytes (leukopenia): Gr1 \<LLN-3000/mm3; Gr2 \<3000-2000/mm3; Gr3 \<2000-1000/mm3; Gr4 \<1000/mm3. Lymphocytes (lymphocytopenia): Gr1 \<LLN-800/mm3; Gr2 \<800-500/mm3; Gr3 \<500-200/mm3; Gr4 \<200/mm3. Platelets (thrombocytopenia): Gr1 \<LLN-75,000/mm3; Gr2 \<75,000-50,000/mm3; Gr3 \<50,000-25,000/mm3; Gr4 \<25,000/mm3. Hemoglobin (anemia): Gr1 \<LLN-10.0 g/dL; Gr2 \<10.0-8.0 g/dL; Gr3 \<8.0-6.5 g/dL; Gr4 \<6.5 g/dL. LLN/ULN=lower/upper limit of normal (normal ranges may vary by local laboratories).

    Time frame: Assessed at baseline, every 2 weeks during cycles 1-6 (6-week cycles), and every 6 weeks after cycle 6. Median number of cycles = 1.0 (range: 1.0 - 7.0).

  5. Number of Participants With Worst Grade of Biochemistry Abnormality Per NCI CTCAE Version 3.0 Criteria

    Grades (gr) 1=mild; gr2=moderate; gr3=severe; gr4=life-threatening. For details of NCI CTCAE laboratory values for each grade, please refer to http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_30. Low Potassium=Hypokalemia, High Potassium=Hyperkalemia, Low Sodium=Hyponatremia, Low Calcium=Hypocalcemia, High Bilirubin=Hyperbilirubinemia, low phosphatase=Hypophosphatemia, Low Potassium=Hypokalemia.

    Time frame: Assessed at baseline, every 2 weeks during cycles 1-6 (6-week cycles), and every 6 weeks after 6 cycles. Median number of cycles = 1.0 (range: 1.0 - 7.0).

Other outcomes

  1. Number of Participants With Disease Progression at 12 Months

    As measured by brain magnetic resonance imaging.

    Time frame: 12 months

07

Results

Posted Aug 28, 2012

Participant flow

Participant flow — Overall Study
MilestoneDasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2
Started63791
Completed00000
Not completed63791
Withdrew: Disease progression/relapse/death33781
Withdrew: Thrombocytopenia, grade 420010
Withdrew: Both progression and toxicity10000

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs

SAE=any untoward medical event that results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires inpatient hospitalization or prolongation. AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Treatment-related(Tx-R)=certainly, probably, possibly related and unknown relationship to study drug. AE grades(Gr) 1=Mild; 2=Moderate; 3=Severe; 4=Life-threatening.

Time frame:
Assessed at baseline, every 2 weeks during cycles 1-6 (6-week cycles), and every 6 weeks after cycle 6. Median number of cycles = 1.0 (range: 1.0 - 7.0).
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs
participantsDasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2
Deaths within 30 days of Tx Discontinuation10100
Tx-R Deaths within 30 days of Tx Discontinuation00000
At Least 1 SAE51440
At Least 1 Tx-R SAE40110
Discontinuations Due to AEs30010
At Least 1 AE63791
At Least 1 Gr 3/4 AE22440
At Least 1 Tx-R AE52571
At Least 1 Tx-R Gr 3/4 AE00000
PrimaryNumber of Participants With Dose-limiting Toxicities (DLTs)

Grades (gr) according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE), version 3.0. DLTs were defined as adverse drug reactions as follows: absolute neutrophil counts \<0.5x10\^9/L (gr4) lasting for 7 consecutive days; febrile neutropenia (neutrophil count \<1x10\^9/L and fever of \>=38.5°C); thrombocytopenia (gr4); any gr3/4 nonhematological toxicity except nausea, vomiting and fever which could be rapidly controlled with appropriate measures; any toxicity which did not allow administering at least 70% of the intended dose intensity for both agents.

Time frame:
The duration for observation of DLT was 2 6-week cycles in participants with escalated dose (QD to BID) and 1 6 -week cycle for participants starting with BID regime. For participants receiving dasatinib at 150 mg, DLTs were only documented over cycle 1.
Reported as:
Number · participants
Number of Participants With Dose-limiting Toxicities (DLTs)
participantsDasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2
Number of Participants With Dose-limiting Toxicities (DLTs)3—34—
PrimaryDeaths Within 30 Days of Protocol Treatment Discontinuation
Time frame:
From time of randomization through within 30 days after protocol treatment discontinuation. Median (full range) number of 6-week treatment cycles was 1.0 (1.0-7.0).
Reported as:
Number · participants
Deaths Within 30 Days of Protocol Treatment Discontinuation
participantsDasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2
Deaths Within 30 Days of Protocol Treatment Discontinuation10100
PrimaryNumber of Participants With Worst Grade of Hematological Toxicity Per NCI CTCAE Version 3.0 Criteria

Neutrophils (neutropenia): Grade (gr)1 \<LLN-1500/mm3; Gr2 \<1500-1000/mm3; Gr3 \<1000-500/mm3; Gr4 \<500/mm3. Leukocytes (leukopenia): Gr1 \<LLN-3000/mm3; Gr2 \<3000-2000/mm3; Gr3 \<2000-1000/mm3; Gr4 \<1000/mm3. Lymphocytes (lymphocytopenia): Gr1 \<LLN-800/mm3; Gr2 \<800-500/mm3; Gr3 \<500-200/mm3; Gr4 \<200/mm3. Platelets (thrombocytopenia): Gr1 \<LLN-75,000/mm3; Gr2 \<75,000-50,000/mm3; Gr3 \<50,000-25,000/mm3; Gr4 \<25,000/mm3. Hemoglobin (anemia): Gr1 \<LLN-10.0 g/dL; Gr2 \<10.0-8.0 g/dL; Gr3 \<8.0-6.5 g/dL; Gr4 \<6.5 g/dL. LLN/ULN=lower/upper limit of normal (normal ranges may vary by local laboratories).

Time frame:
Assessed at baseline, every 2 weeks during cycles 1-6 (6-week cycles), and every 6 weeks after cycle 6. Median number of cycles = 1.0 (range: 1.0 - 7.0).
Reported as:
Number · participants
Number of Participants With Worst Grade of Hematological Toxicity Per NCI CTCAE Version 3.0 Criteria
participantsDasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2
At least 1 Grade 1-4 Neutropenia32250
At least 1 Grade 1-4 Leukopenia53460
At least 1 Grade 1-4 Lymphocytopenia52490
At least 1 Grade 1-4 Thrombocytopenia63691
At least 1 Grade 1-4 Anemia61690
At least 1 Grade 3-4 Neutropenia21040
At least 1 Grade 3-4 Leukopenia11040
At least 1 Grade 3-4 Lymphocytopenia40150
At least 1 Grade 3-4 Thrombocytopenia40250
At least 1 Grade 3-4 Anemia00100
PrimaryNumber of Participants With Worst Grade of Biochemistry Abnormality Per NCI CTCAE Version 3.0 Criteria

Grades (gr) 1=mild; gr2=moderate; gr3=severe; gr4=life-threatening. For details of NCI CTCAE laboratory values for each grade, please refer to http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_30. Low Potassium=Hypokalemia, High Potassium=Hyperkalemia, Low Sodium=Hyponatremia, Low Calcium=Hypocalcemia, High Bilirubin=Hyperbilirubinemia, low phosphatase=Hypophosphatemia, Low Potassium=Hypokalemia.

Time frame:
Assessed at baseline, every 2 weeks during cycles 1-6 (6-week cycles), and every 6 weeks after 6 cycles. Median number of cycles = 1.0 (range: 1.0 - 7.0).
Reported as:
Number · participants
Number of Participants With Worst Grade of Biochemistry Abnormality Per NCI CTCAE Version 3.0 Criteria
participantsDasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2
At least 1 Gr 1-4 Hypokalemia10130
At least 1 Gr 1-4 Hyperkalemia01000
At least 1 Gr 1-4 Hyponatremia10000
At least 1 Gr 1-4 Hypernatremia11050
At least 1 Gr 1-4 Creatinine02000
At least 1 Gr 1-4 Hypocalcemia31320
At least 1 Gr1-4 Hyperbilirubinemia00001
At least 1 Gr 1-4 Aspartate Aminotransferase / AST20460
At least 1 Gr 1-4 Hypophosphatemia11130
At least 1 Gr 3-4 Hypokalemia00010
Other pre-specifiedNumber of Participants With Disease Progression at 12 Months

As measured by brain magnetic resonance imaging.

Time frame:
12 months
Reported as:
Number · participants
Number of Participants With Disease Progression at 12 Months
participantsDasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2
Number of Participants With Disease Progression at 12 Months63791

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2—5/6 (83.3%)6/6 (100%)
Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2—1/3 (33.3%)3/3 (100%)
Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2—4/7 (57.1%)7/7 (100%)
Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2—3/9 (33.3%)9/9 (100%)
Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2—0/1 (0%)1/1 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventDasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2
ConvulsionNervous system disorders0/61/31/72/90/1
EnteritisGastrointestinal disorders0/61/30/70/90/1
Platelet count decreasedInvestigations2/60/30/70/90/1
Neutrophil count decreasedInvestigations0/60/30/72/90/1
Subdural haematomaInjury, poisoning and procedural complications1/60/30/70/90/1
DeathGeneral disorders1/60/31/70/90/1
Pleural effusionRespiratory, thoracic and mediastinal disorders1/60/30/70/90/1
Decreased appetiteMetabolism and nutrition disorders0/60/31/70/90/1
AnaemiaBlood and lymphatic system disorders0/60/31/70/90/1
UrosepsisInfections and infestations0/60/31/70/90/1
Most frequent other events
Showing 10 of 72
Most frequent other events
EventDasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2
Carbon monoxide diffusing capacityInvestigations0/62/33/73/91/1
HeadacheNervous system disorders3/61/34/73/91/1
FatigueGeneral disorders6/63/36/76/91/1
VomitingGastrointestinal disorders4/60/33/75/91/1
Exfoliative rashSkin and subcutaneous tissue disorders1/61/30/71/91/1
Speech disorderNervous system disorders1/62/31/71/90/1
AlopeciaSkin and subcutaneous tissue disorders1/62/31/71/90/1
Peripheral motor neuropathyNervous system disorders4/61/33/75/90/1
NauseaGastrointestinal disorders4/61/34/76/90/1
Peripheral sensory neuropathyNervous system disorders2/62/32/71/90/1

Baseline characteristics

Age Continuous
Age Continuous(years)Dose Level 1ADose Level 1BDose Level 2Dose Level 3ADose Level 3BTotal
Median58.8 (41.3 to 70.7)57.7 (48.9 to 57.7)53.6 (42.4 to 64.0)49.7 (38.8 to 66.8)51.1 (51.1 to 51.1)54.8 (38.8 to 70.7)
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level 1ADose Level 1BDose Level 2Dose Level 3ADose Level 3BTotal
Female102306
Male5356120
Histological Diagnosis of Primary Disease
Histological Diagnosis of Primary Disease(participants)Dose Level 1ADose Level 1BDose Level 2Dose Level 3ADose Level 3BTotal
glioblastoma multiforme6258122
glioblastoma w/ oligodendroglial component012104
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Dose Level 1ADose Level 1BDose Level 2Dose Level 3ADose Level 3BTotal
Grade 06214114
Grade 10154010
Grade 2001102
08

Study locations

5 sites
  • Local Institution
    Paris Cedex, 75013, France
  • Local Institution
    Bologna, 40139, Italy
  • Local Institution
    Nijmegen, 6525 GA, Netherlands
  • Local Institution
    Rotterdam, 3075 EA, Netherlands
  • Local Institution
    Lausanne, 1011, Switzerland
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2009
First posted
Jul 29, 2009
Start
Oct 2009
Primary completionActual
May 2011
CompletionActual
May 2011
Results first posted
Aug 28, 2012
Last update
Aug 31, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00948389
Responsible party
Sponsor
First posted
Jul 29, 2009
Start date
Oct 2009
Primary completion
May 2011
Completion
May 2011
Results posted
Aug 28, 2012
Last update
Aug 31, 2012

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dasatinib · Lomustine

Start the discussion